BioSpace News Archive

FDA authorizes new IND for the study of CLBS119 in COVID-19 patients who experienced respiratory failure

In the first calendar quarter of 2020, Utah Medical Products, Inc. attained results consistent with 1Q 2019, despite realizing a negative impact from the public response to the corona virus.

Fruit Street Health, a leading telehealth company funded and guided by physicians, today announced the launch of CovidMD™ (www.CovidMD.com), a risk assessment, triage, and telemedicine platform created to help the healthcare system safely and efficiently respond to the COVID-19 pandemic.

Edwards Lifesciences Corporation, the global leader in patient-focused innovations for structural heart disease and critical care monitoring, reported financial results for the quarter ended March 31, 2020.

eHealth, Inc. (NASDAQ: EHTH), a leading private online health insurance marketplace, announces today its financial results for the first quarter ended March 31, 2020.

Integra LifeSciences Holdings Corporation, a leading global medical technology company, announced that its 2020 Annual Meeting of Stockholders location will change from its headquarters to a virtual meeting by remote communication.

The Human Vaccines Project, a global nonprofit consortium is launching the COVID Vaccine Initiative, with the goal to ensure the development of safe, effective, accessible vaccines for those most vulnerable to COVID-19.

Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, today jointly announced with Eli Lilly and Company (“Lilly”, NYSE: LLY) that the National Medical Products Administration (NMPA) of China has accepted the supplemental New Drug Application (sNDA) for Tyvyt®

GlaxoSmithKline plc (LSE/NYSE:GSK) today announced data from an updated analysis of the GARNET trial, which demonstrated that dostarlimab, an investigational anti-programmed death-1 (PD-1) monoclonal antibody, provided clinically meaningful results in women with recurrent or advanced mismatch repair-deficient (dMMR) endometrial cancer who progressed on or after a platinum-based regimen.

Notice is hereby given that Faruqi & Faruqi, LLP has filed a class action lawsuit in the United States District Court for the Southern District of New York, Case No. 1:20-cv-02847 on behalf of shareholders of Progenics Pharmaceuticals, Inc. (“Progenics” or the “Company”) (NASDAQ:PGNX) who have been harmed by Progenics’ and its board of directors’ (the “Board”) alleged violations of Sections 14(a) and 20(a)